Isoniazid

Generic Name: Isoniazid

Brand Names: Isonarif, Isotamine, Isotamine B, Rifamate, Rifater

Drug Type: Small Molecule

Chemical Formula: C_₆H_₇N_₃O

CAS Number: 54-85-3

Unique Ingredient Identifier: V83O1VOZ8L

Background: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication: Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions: Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis

Associated Therapies: -

Clinical Trials

Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System

Phase 4

Completed

Conditions: IUCD Complication

Interventions: Drug: Placebo Comparator
Drug: INH

First Posted Date: 2020-08-05

Last Posted Date: 2022-05-13

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 220

Registration Number: NCT04500028

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion

Phase 4

Completed

Conditions: IUCD Complication

Interventions: Drug: Placebo Comparator
Drug: INH

First Posted Date: 2020-08-05

Last Posted Date: 2021-09-29

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 130

Registration Number: NCT04500015

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion

Phase 4

Completed

Conditions: IUCD Complication

Interventions: Drug: Placebo Comparator
Drug: INH

First Posted Date: 2020-08-05

Last Posted Date: 2021-08-09

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 220

Registration Number: NCT04499989

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients

Phase 4

Completed

Conditions: Infertility, Female

Interventions: Drug: Placebo
Drug: INH

First Posted Date: 2020-08-05

Last Posted Date: 2021-09-29

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 150

Registration Number: NCT04500522

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Phase 3

Not yet recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: High-dose rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Rifampicin

First Posted Date: 2020-07-24

Last Posted Date: 2020-07-24

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 926

Registration Number: NCT04485156

Locations: 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of

Efficacy and Safety of Intravenous Treatment of Tuberculosis

Terminated

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Ethambutol

First Posted Date: 2019-11-04

Last Posted Date: 2019-11-07

Lead Sponsor: Yuria-Pharm

Target Recruit Count: 166

Registration Number: NCT04150367

Locations: 🇺🇦
Regional Antituberculosis Dispensary, Kherson, Ukraine
🇺🇦
Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine
🇺🇦
Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine

and more 5 locations

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Imatinib
Drug: Isoniazid
Drug: Rifabutin

First Posted Date: 2019-03-27

Last Posted Date: 2023-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT03891901

Locations: 🇺🇸
Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States

Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis

Not Applicable

Conditions: Tuberculous Meningitis

Interventions: Drug: Isoniazid

First Posted Date: 2018-12-27

Last Posted Date: 2021-02-01

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 676

Registration Number: NCT03787940

Locations: 🇨🇳
Jiangxi Provincial Chest Hospital, Nanchang, China
🇨🇳
Zunyi Medical College affiliated Hospital, Zunyi, China
🇨🇳
Jiamusi Infectious Disease Hospital, Jiamusi, China

and more 1 locations

Tuberculosis Clinical Trials Consortium Study 35

Phase 1

Recruiting

Conditions: Latent Tuberculosis

Interventions: Drug: Rifapentine
Drug: Isoniazid

First Posted Date: 2018-11-05

Last Posted Date: 2023-09-01

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 72

Registration Number: NCT03730181

Locations: 🇿🇦
Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch, South Africa

A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

Not Applicable

Completed

Conditions: Drug-Induced Liver Injury
Adverse Drug Event
Tuberculosis

Interventions: Drug: Isoniazid

First Posted Date: 2018-09-11

Last Posted Date: 2020-02-28

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 16

Registration Number: NCT03665402

Locations: 🇰🇷
Seoul National University Hospital Clinical Trials Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy